Assessing Aurinia Pharmaceuticals After Its 80% 2025 Surge and Lupus Nephritis Momentum [Yahoo! Finance]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Yahoo! Finance
This breakdown will help you decide whether the current price matches the underlying value. The stock has climbed 80.7% year to date and 64.6% over the last year, with a 253.0% gain over three years that signals investors have rapidly rewritten their expectations for the business. Much of this momentum has been driven by growing optimism around Aurinia's core lupus nephritis therapy and its commercial execution, alongside a shifting competitive landscape in autoimmune treatments. Investors have also been reacting to regulatory and pipeline updates that shape expectations for how durable and profitable that core franchise could become. Right now, Aurinia scores a 3/6 valuation check score , suggesting it screens as undervalued on half of the key metrics tracked, and fairly priced or stretched on the rest. In the sections ahead we will unpack what different valuation approaches say about that score, and then close with a way to think about Aurinia's longer term value story. Auri
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms [Seeking Alpha]Seeking Alpha
- Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was given a new $16.00 price target on by analysts at Leerink Partners.MarketBeat
- A Look at Aurinia Pharmaceuticals (NasdaqGM:AUPH) Valuation After Recent Share Price Surge [Yahoo! Finance]Yahoo! Finance
AUPH
Earnings
- 11/4/25 - Beat
AUPH
Sec Filings
- 11/24/25 - Form 4
- 11/24/25 - Form 4
- 11/4/25 - Form 8-K
- AUPH's page on the SEC website